CompletedInterventional · Phase 2NCT03557359 ↗A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating Agents
CompletedInterventional · Phase 1NCT03625505 ↗A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaEllen K. RitchiePIInterventionDrug: Venetoclax · Drug: GilteritinibDatesOct 2018 – Aug 2021SponsorAbbVie Inc.Acute Myeloid Leukemia (AML)
CompletedInterventional · Phase 3NCT03651128 ↗A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)Roger N PearsePIInterventionBiological: bb2121 · Drug: Daratumumab · Drug: Pomalidomide · Drug: Dexamethasone · Drug: Bortezomib · Drug: Ixazomib · Drug: Lenalidomide · Drug: Carfilzomib · Drug: ElotuzumabDatesApr 2019 – Apr 2026SponsorCelgene CorporationMultiple Myeloma
CompletedInterventional · Phase 4NCT04377555 ↗An Open-Label, Prospective, Single-arm, Multi-center Study to Assess Disease Activity and Biomarkers of Neuronal Damage in Minority Patients With Relapsing Multiple Sclerosis Receiving Treatment With OcrelizumabUlrike W. KaunznerPIInterventionDrug: OcrelizumabDatesJul 2020 – Dec 2022SponsorGenentech, Inc.Multiple Sclerosis, Relapsing
CompletedInterventional · Phase 2NCT04847739 ↗Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II)Dana Jeremy LukinPIInterventionProcedure: Seton Placement · Drug: AVB-114DatesSep 2021 – May 2025 (est.)SponsorAvobis Bio, LLCPerianal FistulaCrohn's Disease
CompletedExpanded accessNCT05462639 ↗ELRANATAMAB (PF-06863135) MONOTHERAPY EXPANDED ACCESS PROTOCOL FOR TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY AND HAVE NO ACCESS TO OTHER COMPARABLE/ALTERNATIVE THERAPYRuben NiesvizkyPIInterventionDrug: Elranatamab (PF-06863135)DatesStarted Dec 2022SponsorPfizer, Inc.Multiple Myeloma
CompletedExpanded accessNCT05757973 ↗64407564MMY4003: 64407564MMY4003 - Talquetamab NPP GlobalRuben NiesvizkyPIInterventionDrug: TalquetamabDatesStarted Jul 2023SponsorJanssen Research & Development, LLCRelapsed or Refractory Multiple Myeloma
CompletedInterventional · Not applicableNCT06676072 ↗Safety and Effectiveness of the TactiFlex SE Catheter and Volt Pulsed Field Ablation (PFA) Generator in Subjects With Paroxysmal Atrial FibrillationSteven M MarkowitzPIInterventionDevice: PFA Ablation catheterDatesNov 2024 – Apr 2026SponsorAbbott Cardiovascular Systems, Inc.Atrial Fibrillation (AF)Atrial ArrhythmiaParoxysmal AF+1 more